Valdespino JL, Conde-González CJ, Olaiz-Fernández G, Palma O, Sepúlveda J

Language: Spanish
References: 26
Page: 404-411
PDF size: 214.41 Kb.

ABSTRACT

Objective. To estimate the prevalence of chronic hepatitis B infection and carrier status in Mexico; to analyze the frequency and distribution of hepatitis B markers in relation to the demographic and geographic variables and to identify risk factors. Materials and Methods. A total of 12 014 sera samples from the 2000 National Health Survey that were randomly selected for Anti-HBc and HBsAg were studied. The sera were collected between November 1999 and June 2000 on a national level. Results. Seroprevalence for anti-HBc and HBsAg were 3.3% (CI 95%: 2.8-3.9) and 0.21% (0.11-0.37), respectively. Odds ratios adjusted by age for anti-HBc were: 15.3 for subjects 50 to 59 years old as compared with adults less than 29 years of age; 2.6 for residents in the southern region of the country as compared with residents in the central region; 4.6 for laborers as compared with business owners; 2.1 for women having had stillbirths; and 1.7 for adults having initiated sexual relations before 25 years of age. Conclusion. The epidemiological pattern for hepatitis B in Mexico is lower than the data worldwide. Nevertheless, it is of concern that 1.7 million Mexicans have suffered from the infection caused by this virus and 107 000 suffer from a chronic carrier status.

REFERENCES

1. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54(RR-16):1-31.

2. Vázquez-Flores JA, Marín LRA, Sánchez-Guerrero AS. La seguridad de las reservas sanguíneas en la República Mexicana durante los años 1999 a 2003. Rev Invest Clin 2006;58:1.

3. Programa de Acción: Infancia. En: SSA, ed. México: SSA, 2002.

4. Programa de Acción. En: Sistema Nacional de Vigilancia Epidemiológica SSA, ed. México: SSA, 2001.

5. OPS/OMS. Medicina transfusional en los países del Caribe y Latinoamérica, 2000-2003. Informe técnico 2005.

6. Silveira TR, Fonseca JC, Rivera L, et al. Hepatitis B seroprevalence in Latin America. Rev Panam Salud Publica 1999;6(6):378-383.

7. Ayala-Gaytán JJ, Guerra-Avalos FJ, Mora-Brondo P, et al. Prevalence of viral markers for hepatitis B, C and human immunodeficiency virus in volunteer blood donors in Northeast Mexico. Rev Gastroenterol Mex 1997;62(4):250-253.

8. Carreto-Vélez MA, Carrada-Bravo T, Martínez-Magdaleno A. Seroprevalence of HBV, HCV, and HIV among blood donors in Irapuato, Mexico. Salud Publica Mex 2003;45(Supp 5):S690-S693.

9. Rivera-López MR, Zavala-Méndez C, Arenas-Esqueda A. Prevalence for seropositivity for HIV, hepatitis B and hepatitis C in blood donors. Gac Med Mex 2004;140(6):657-660.

10. Vázquez-Martínez JL, Coreno-Juárez MO, Montano-Estrada LF, et al. Seroprevalence of hepatitis B in pregnant women in Mexico. Salud Publica Mex 2003;45(3):165-170.

11. Hyams KC, Escamilla J, Lozada-Romero R, et al. Hepatitis B infection in a non-drug abusing prostitute population in Mexico. Scand J Infect Dis 1990;22(5):527-531.

12. Juárez-Figueroa L, Uribe-Salas F, Conde-González C, et al. Low prevalence of hepatitis B markers among Mexican female sex workers. Sex Transm Infect 1998;74(6):448-450.

13. Kershenobich D, Hurtado R, Collawn C, et al. Seroprevalence of viral markers of hepatitis B among health professionals. Multicenter study in Mexico. Rev Invest Clin 1990;42(4):251-256.

14. Villasis-Keever MA, Pena LA, Miranda-Novales G, et al. Prevalence of serological markers against measles, rubella, varicella, hepatitis B, hepatitis C, and human immunodeficiency virus among medical residents in Mexico. Prev Med 2001;32(5):424-428.

15. Alvarado-Esquivel C, Arreola-Valenzuela MA, Mercado-Suárez MF, et al. Hepatitis B virus infection among inpatients of a psychiatric hospital of Mexico. Clin Pract Epidemol Ment Health 2005;1:10.

16. Alvarado-Esquivel C, Sablón E, Martínez-García S, et al. Hepatitis virus and HIV infections in inmates of a state correctional facility in Mexico. Epidemiol Infect 2005;133(4):679-685.

17. Alvarez-Muñoz T, Bustamante-Calvillo E, Martínez-García C, et al. Seroepidemiology of the hepatitis B and delta in the southeast of Chiapas, Mexico. Arch Invest Med (Mex) 1989;20(2):189-195.

18. Echevarría JM, León P. Epidemiology of viruses causing chronic hepatitis among populations from the Amazon Basin and related ecosystems. Cad Saude Publica 2003;19(6):1583-1591.

19. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89(1):14-18.

20. Valdespino JL, Olaiz G, MP L-B, et al. Encuesta Nacional de Salud 2000. Tomo 1, Vivienda, población y utilización de servicios de salud. Cuernavaca, México: Instituto Nacional de Salud Publica, 2003.

21. Ley de Información Estadística y Geográfica. México: Diario Oficial de la Federación; Diciembre 30, 1980.

22. Varela-Ramírez A, Mejía A, García D, et al. HIV infection and risk behavior of Hispanic farm workers at the west Texas-Mexico border. Ethn Dis 2005;15(4;Suppl 5):-92-96.

23. Tapia-Aguirre V, Arillo-Santillán E, Allen B, et al. Associations among condom use, sexual behavior, and knowledge about HIV/AIDS. A study of 13,293 public school students. Arch Med Res 2004;35(4):334-343.

24. Allen B, Cruz-Valdez A, Rivera-Rivera L, et al. Affection, kisses, and condoms: the ABC of sexual practices of female sex workers in Mexico City. Salud Publica Mex 2003;45(Supp 5):S594-S607.

25. Pulerwitz J, Izazola-Licea JA, Gortmaker SL. Extrarelational sex among Mexican men and their partners’ risk of HIV and other sexually transmitted diseases. Am J Public Health 2001;91(10):1650-1652.

26. Fay OH. Hepatitis B in Latin America: epidemiological patterns and eradication strategy. The Latin American Regional Study Group. Vaccine 1990;8(Suppl):S100-S106; discussion S134-S139.